人才队伍

       目前担任浙江大学药物安全性评价研究中心主任、浙江省抗肿瘤药物临床前研究重点实验室主任、浙江省未来科技城创新药物早期成药性评价公共服务平台主任、浙江大学（杭州）创新医药研究院副院长等职。主要研究方向是肿瘤药理学和药物毒理学。重点聚焦于分化诱导剂干预骨肉瘤和白血病干性特征和恶性演进的关键分子机制，发现了分化诱导剂在干预肿瘤细胞-肿瘤相关巨噬细胞交互作用中的新功能；揭示了Klf4+干细胞亚群的富集在肿瘤细胞化疗耐受过程中的关键作用；研究了MDM2蛋白在骨肉瘤耐受分化诱导剂中的关键作用，发现了一系列潜在的分化治疗新靶点及新治疗方案。发现了细胞自噬、氧化应激、少突胶质细胞分化等参与了抗肿瘤药物的毒性过程，并集中研究HMGB1、P38、MDM2、Olig1、HDAC等蛋白靶点在这些过程中的作用。

  作为负责人共承担国家重点研究计划课题1项，国家自然科学基金重大研究计划（培育）1项，国家自然科学基金项目7项，十一五国家新药创制重大专项课题2项，省部级课题5项。共发表SCI论文155篇，其中通讯作者62篇。获得国家发明专利44项，省级二等奖3项，中国专利优秀奖1项。并获得教育部新世纪优秀人才、浙江省自然科学基金杰青团队、浙江省“新世纪151人才工程”第一层次、浙江省卫生高层次创新人才等人才项目的支持，2007年度浙江省青年科技奖获得者。

近年文章：

1. Ying M, Shao X, Jing H, Liu Y, Qi X, Cao J, Chen Y, Xiang S, Song H, Hu R, Wei G, Yang B*, He Q*. Ubiquitin-dependent Degradation of CDK2 Drives the Therapeutic Differentiation of AML by Targeting PRDX2. Blood. 2018 Jun 14;131(24):2698-2711.

2. Zhu H, Wang D, Yuan T, Yan F, Zeng C, Dai X, Chen Z, Chen Y, Zhou T, Fan G, Ying M, Cao J, Luo P, Liu X, Hu Y, Peng Y, He Q *, Yang B *. Multi-kinase inhibitor CT-707 targets liver cancer by interrupting the hypoxia-activated IGF-1R-YAP axis. Cancer Research. 2018 Jul 15;78(14):3995-4006. 

3. Luo P*, Xu Z, Li G, Yan H, Zhu Y , Zhu H, Ma S, Yang B*, He Q*. HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport. Autophagy.Accepted.2018

4. Hong Zhu^#,Lin-Lin Chang^#,Fang-Jie Yan, Yan Hu, Chen-Ming Zeng, Tian-Yi Zhou, Tao Yuan, Mei-Dan Ying, Ji Cao, He Q *, Yang B*. AKR1C1 Activates STAT3 to Promote the Metastasis of .Non-Small Cell Lung Cancer. Theranostics. 2018; 8(3): 676-692.

5. Weng Q, Wang J, Wang J, Wang J, Sattar F, Zhang Z, Zheng J, Xu Z, Zhao M, Liu X, Yang L, Hao G, Fang L, Lu QR, Yang B*, He Q*. Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization.Cell Death Dis. 2018 Feb 14;9(2):251. 

6. Qian Zhou^#, Miao Xian^#, Senfeng Xiang, Danyan Xiang, Xuejing Shao, Jincheng Wang, Ji Cao, Xiaochun Yang, Bo Yang, Meidan Ying* and Qiaojun He*. All-trans retinoic acid prevents osteosarcoma metastasis by inhibiting M2 polarization of tumor-associated macrophages. Cancer Immunology Research.   2017 

7. Yangling Li, Miao Xian, Bo Yang, Meidan Ying* and Qiaojun He*. Inhibition of KLF4 by statins reverses Adriamycin-induced metastasis and cancer stemness in osteosarcoma cells. Stem cell reports. 2017. 

8. Miao Xian^#, Handi Cao^#, Ji Cao, Xuejing Shao, Difeng Zhu, Ning Zhang, Ping Huang,Weixu Li, Bo Yang, Meidan Ying* and Qiaojun He*. Bortezomib sensitizes human osteosarcoma cells to adriamycin-induced apoptosis through ROS-dependent activation of p-eIF2α/ATF4/CHOP axis. International Journal of Cancer. 2017 

9. Xu L, Zhu Y, Shao J, Chen M, Yan H, Li G, Zhu Y, Xu Z, Yang B, Luo P*,He Q *. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1. British Journal of Cancer. (2017) 1–10 

10.  Ying M, Zhang L, Zhou Q , Shao X, Cao J , Zhang N , Li W , Zhu H, Yang B , He Q *. The E3 ubiquitin protein ligase MDM2 dictates all-trans retinoic acid-induced osteoblastic differentiation of osteosarcoma cells by modulating the degradation of RARα. Oncogene. 2016 January 18; 35, 4358–4367. 

11.  Xu Z, Shao J, Li L, Peng X, Chen M, Li G, Yan H, Yang B, Luo P*, He Q*. All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARalpha-mediated DNA damage. BMC cancer 2016 Jan 5;16:2. 

12.  Zhang L#, Zhou Q#, Zhang N, Li W, Ying M, Ding W, Yang B*,He Q*. E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα. Cell Cycle. 2014;13(8): 1277-87. doi: 10.4161/cc.28190.4.6

13.  Cai TY, Liu XW, Zhu H, Cao  J, Zhang J, Ding L, Lou JS, He Q*, Yang B*. Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α. Mol Cancer Ther. 2014 Mar;13(3):630-42. 

14.  Li Y, Luo P, Wang J, Dai J, Yang X, Wu H, Yang B*, He Q*.  Autophagy blockade sensitizes the anticancer activity of CA-4 via JNK-Bcl-2 pathway. Toxicol Appl Pharmacol. 2014 Jan 15;274(2):319-27. 

15.  Wu Y, Fu Y, Zheng L, Lin G, Ma J, Lou J, Zhu H, He Q*, Yang B*. Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis. Cancer Lett. 2014 Jan 1;342(1):82-91. 

16.  Ying M, Zhou X, Zhong L, Lin N, Jing H, Luo P, Yang X, Song H, Yang B*, He Q*. Bortezomib sensitizes human acute myeloid leukemia cells to all-trans-retinoic acid-induced differentiation by modifying the RARα/STAT1 axis. Mol Cancer Ther. 2013 Feb;12(2):195-206.   

17.  Xue T, Luo P, Zhu H, Zhao Y, Wu H, Gai R, Wu Y, Yang B, Yang X*, He Q*. Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes. Toxicol Appl Pharmacol. 2012 Jun 15;261(3):280-91. 

18.  Zheng L, Yang W, Zhang C, Ding WJ, Zhu H, Lin NM, Wu HH, He Q*, Yang B*. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett. 2011 Oct 1;309(1):27-36.  

19.  Zhang C, Cai TY, Zhu H, Yang L, Jiang H, Dong XW, Hu Y, Lin NM, He Q*, Yang B*. Synergistic anti-tumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther. 2011 Jul;10(7):1264-75.  

20.  Zhao Y, Xue T, Yang X, Zhu H, Ding X, Lou L, Lu W, Yang B*, He Q*. Autophagy plays an important role in Sunitinib-mediated cell death in H9c2 cardiac muscle cells. Toxicol Appl Pharmacol. 2010 Oct 1;248(1):20-7.